Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.

Inclusion Criteria:

Subjects must give a written informed consent before any assessment is performed.

Subjects must have completed the 104-week treatment period in the core study Subjects who
are deemed by the investigator to benefit from continued secukinumab therapy.

Exclusion Criteria:

Use of other investigational drugs except for secukinumab during the core study.

Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female
after conception and until the termination of gestation, confirmed by a positive hCG
laboratory test.

Women of child-bearing potential, defined as all women physiologically capable of becoming
pregnant, unless they are using effective methods of contraception during dosing of study
treatment.